Paul C Hendrie
Overview
Explore the profile of Paul C Hendrie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal K, Othus M, Ali Z, Russell K, Shaw C, Percival M, et al.
Blood Adv
. 2024 Oct;
8(24):6161-6170.
PMID: 39368804
Febrile neutropenia (FN) is the most common reason for hospital readmission after chemotherapy for acute myeloid leukemia (AML) and is a major driver of health care resource utilization. Although FN...
2.
Zarling L, Stevenson P, Soma L, Martino C, Percival M, Halpern A, et al.
Eur J Haematol
. 2023 Sep;
111(6):863-871.
PMID: 37670560
Objectives: We recently performed a single-arm phase II trial of DA-EPOCH in adults with acute lymphoblastic leukemia (ALL). We sought to compare these results to those with standard Hyper-CVAD. Methods:...
3.
Halpern A, Rodriguez-Arboli E, Othus M, Garcia K, Percival M, Cassaday R, et al.
Blood Adv
. 2023 Jun;
7(17):4950-4961.
PMID: 37339483
The multikinase inhibitor sorafenib improves event-free survival (EFS) when used with 7 + 3 in adults with newly-diagnosed acute myeloid leukemia (AML), irrespective of the FLT3-mutation status. Here, we evaluated...
4.
Chen K, Hendrie P, Naresh K
Ann Hematol
. 2023 Apr;
102(6):1613-1615.
PMID: 37016166
No abstract available.
5.
Cassaday R, Zarling L, Garcia K, Sala-Torra O, Stevenson P, Martino C, et al.
Leuk Lymphoma
. 2023 Mar;
64(5):927-937.
PMID: 36938892
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide,...
6.
Kopmar N, Gooley T, Curley N, Russell K, Shaw C, Schonhoff K, et al.
Leuk Lymphoma
. 2023 Mar;
64(5):1057-1059.
PMID: 36896478
No abstract available.
7.
Zhang M, Othus M, Shaw C, Schonhoff K, Halpern A, Appelbaum J, et al.
Leuk Lymphoma
. 2023 Mar;
64(5):990-996.
PMID: 36891630
Patients with acute myeloid leukemia (AML) who have failed hypomethylating agents (HMA) have a poor prognosis. We examined whether high intensity induction chemotherapy could abrogate negative outcomes in 270 patients...
8.
Godwin C, Rodriguez-Arboli E, Othus M, Halpern A, Appelbaum J, Percival M, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740603
Gemtuzumab ozogamicin (GO) improves outcomes when added to intensive AML chemotherapy. A meta-analysis suggested the greatest benefit when combining fractionated doses of GO (GO3) with 7 + 3. To test...
9.
Wu B, Konnick E, Kimble E, Hendrie P, Shinohara M, Moshiri A
J Cutan Pathol
. 2022 Mar;
49(8):727-730.
PMID: 35332933
Several mutations and gene fusions involved in the mitogen-activated protein kinase (MAPK) pathway have been reported in histiocytic neoplasms including Langerhans cell histiocytosis and non-Langerhans-cell histiocytosis (NLCH). We identified a...
10.
Lahman M, Schmitt T, Paulson K, Vigneron N, Buenrostro D, Wagener F, et al.
Sci Transl Med
. 2022 Feb;
14(631):eabg8070.
PMID: 35138909
Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient,...